Axon Enterprise, Inc. (NASDAQ:AXON) Director Julie A. Cullivan Sells 515 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Julie A. Cullivan sold 515 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $214.47, for a total value of $110,452.05. Following the completion of the transaction, the director now owns 5,367 shares of the company’s stock, valued at approximately $1,151,060.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Axon Enterprise Trading Down 0.6 %

NASDAQ:AXON opened at $211.93 on Wednesday. The company has a market capitalization of $15.84 billion, a P/E ratio of 158.16 and a beta of 0.87. The stock’s 50 day moving average price is $196.08 and its 200 day moving average price is $203.35. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.98 and a current ratio of 3.38. Axon Enterprise, Inc. has a 52 week low of $109.31 and a 52 week high of $229.95.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.33 by $0.47. The company had revenue of $374.61 million during the quarter, compared to the consensus estimate of $347.53 million. Axon Enterprise had a net margin of 7.24% and a return on equity of 10.88%. On average, research analysts forecast that Axon Enterprise, Inc. will post 1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on AXON shares. Barclays decreased their target price on shares of Axon Enterprise from $256.00 to $239.00 and set an “overweight” rating for the company in a report on Wednesday, August 9th. TheStreet cut shares of Axon Enterprise from a “b-” rating to a “c+” rating in a research report on Friday, May 26th. Morgan Stanley initiated coverage on Axon Enterprise in a report on Tuesday, August 22nd. They issued an “equal weight” rating and a $230.00 target price for the company. Northland Securities lifted their price target on Axon Enterprise from $227.00 to $235.00 and gave the company an “outperform” rating in a report on Friday, August 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $240.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $244.73.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently bought and sold shares of AXON. American Century Companies Inc. increased its holdings in shares of Axon Enterprise by 103.8% during the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 3,155 shares during the last quarter. Private Advisor Group LLC grew its holdings in Axon Enterprise by 40.3% during the first quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 994 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in Axon Enterprise by 12.3% during the first quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock valued at $5,247,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Trust N.A. raised its position in shares of Axon Enterprise by 4.7% in the first quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock valued at $517,000 after purchasing an additional 168 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Axon Enterprise by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock worth $32,545,000 after buying an additional 4,897 shares during the last quarter. 76.52% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.